The text starts here.

Products

Our Products

Eisai positions “neurology” and “oncology” as two strategically important areas where we can discover “Ricchi”, areas where patients true needs remain unmet and we can become a front-runner. Accordingly,we are promoting drug discovery activities in these two areas.

In addition, Eisai is committed to maximizing value for patients by developing additional formulations / expanding indications of our four global brands: Halaven®, Lenvima®, Fycompa®, and BELVIQ®.

In the neurology area, our in-house discovered and developed antiepileptic drug Fycompa® is available in Europe, the Americas, and Asia, and was launched in Japan in May 2016. Aricept® was first launched in January 1997 in the United States and is now approved in over 90 countries worldwide. Moreover, as a leading pharmaceutical company in the development of dementia treatments, we are also expanding our activities to promote early diagnosis and early treatment of dementia. In Japan, Aricept® was additionally approved for the treatment of dementia with Lewy bodies in September 2014.
Regarding our antiobesity agent BELVIQ® in the United States, in addition to the original twice-daily formulation, a new once-daily formulation BELVIQ XR® was launched in October 2016.

In the oncology area, Halaven®, a novel anticancer agent discovered and developed in-house, has been approved for the treatment of breast cancer and malignant soft tissue sarcoma in over 60 countries, including Japan, the United States, in Europe, and in Asia. Lenvima®, another anticancer agent discovered and developed in-house, has been approved for the treatment of thyroid cancer in over 50 countries, including Japan, the United States, in Europe, and in Asia. Additionally, it has been approved for combination therapy with everolimus for renal cell carcinoma in the United States and Europe in May 2016 and September 2016 respectively. (In Europe, the brand name for this indication is Kisplyx®.)

(Information current as of June 2017)

Major Products

  Sales Regions
Four Global Brands
  Halaven (anticancer agent)
  Lenvima (anticancer agent)
  Fycompa (antiepileptic agent)
  BELVIQ (antiobesity agent)
 
Japan, Americas, Europe, Asia
Japan, Americas, Europe, Asia
Japan, Americas, Europe, Asia
US
Pariet/AcipHex (proton-pump inhibitor) Japan, US, Europe, China, Asia
Aricept (treatment for Alzheimer's disease / dementia with Lewy bodies) Japan, US, Europe, China, Asia
Humira (fully human anti-TNF-α monoclonal antibody) Japan, South Korea, Taiwan

* Pariet is marketed in Japan by EA Pharma.

* Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan and the Philippines.

(Information current as of June 2017)

Major Products by Region

Japan Prescription Pharmaceuticals
Humira (fully human anti-TNF-α monoclonal antibody)
Aricept (treatment for Alzheimer's disease / dementia with Lewy bodies)
Lyrica (pain treatment for neuropathic pain / fibromyalgia)
Pariet (proton-pump inhibitor)*
Methycobal (peripheral neuropathy treatment)
Lunesta (insomnia treatment)
Halaven (anticancer agent)
Warfarin (oral anticoagulant)
Livact (osteoporosis treatment)*
Elental (branched-chain amino acid preparation)*
Actonel (osteoporosis treatment)
Lenvima (anticancer agent)
Fycompa (antiepileptic agent)
Consumer Healthcare (Over-the-Counter) Products
Chocola BB group (including Vitamin B2 preparation Chocola BB Plus)
Americas** Aloxi (antiemetic agent)
Halaven (anticancer agent)
Lenvima (anticancer agent)
Banzel (antiepileptic agent)
AcipHex (proton-pump inhibitor)
Fycompa (antiepileptic agent)
BELVIQ (antiobesity agent)
China Methycobal (peripheral neuropathy treatment)
Stronger Neo-Minophagen C / Glycyron tablets (liver disease / allergic disease treatment)
Aricept (treatment for Alzheimer's disease)
Pariet (proton-pump inhibitor)
Asia Aricept (treatment for Alzheimer's disease)
Humira (fully human anti-TNF-α monoclonal antibody)
Pariet (proton-pump inhibitor)
Methycobal (peripheral neuropathy treatment)
Halaven (anticancer agent)
Fycompa (antiepileptic agent)
Lenvima (anticancer agent)
Europe Halaven (anticancer agent)
Zonegran (antiepileptic agent)
Fycompa (antiepileptic agent)
Zebinix (antiepileptic agent)
Lenvima/Kisplyx (anticancer agent)
Inovelon (antiepileptic agent)

*  Marketed by EA Pharma.

** The U.S. is the only country in the Americas where Eisai markets AcipHex and BELVIQ.

(Information current as of June 2017)

Related Links